| Literature DB >> 30853453 |
Yong Liu1, Xianjin Bi1, Jiachuan Xiong1, Wenhao Han1, Tangli Xiao1, Xinli Xu1, Ke Yang1, Chi Liu1, Wei Jiang1, Ting He1, Yanlin Yu1, Yan Li1, Jingbo Zhang1, Bo Zhang1, Jinghong Zhao2.
Abstract
Renal fibrosis is the main pathological characteristic of chronic kidney disease (CKD), whereas the underlying mechanisms of renal fibrosis are not clear yet. Herein, we found an increased expression of microRNA-34a (miR-34a) in renal tubular epithelial cells of patients with renal fibrosis and mice undergoing unilateral ureteral obstruction (UUO). In miR-34a-/- mice, miR-34a deficiency attenuated the progression of renal fibrosis following UUO surgery. The miR-34a overexpression promoted epithelial-to-mesenchymal transition (EMT) in cultured human renal tubular epithelial HK-2 cells, which was accompanied by sharp downregulation of Klotho, an endogenous inhibitor of renal fibrosis. Luciferase reporter assay revealed that miR-34a downregulated Klotho expression though direct binding with the 3' UTR of Klotho. Conversely, overexpression of Klotho prevented miR-34a-induced EMT in HK-2 cells. Furthermore, results showed that miR-34a was induced by transforming growth factor β1 (TGF-β1) through p53 activation, whereas dihydromyricetin could inhibit TGF-β1-induced miR-34a overexpression. Accordingly, dihydromyricetin administration dramatically restored the aberrant upregulation of miR-34a and Klotho reduction in obstructed kidney, and markedly ameliorated renal fibrosis in the Adriamycin nephropathy and UUO model mice. These findings suggested that miR-34a plays an important role in the progression of renal fibrosis, which provides new insights into the pathogenesis and treatment of CKD.Entities:
Keywords: Klotho; TGF-β1; dihydromyricetin; microRNA-34a; renal fibrosis
Mesh:
Substances:
Year: 2019 PMID: 30853453 PMCID: PMC6520492 DOI: 10.1016/j.ymthe.2019.02.009
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454